Effects of Donepezil,Galantamine and Rivastigmine in 938 Italian Patients with Alzheimer’s Disease

[1]  H. Soininen,et al.  Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. , 2009, Current Alzheimer research.

[2]  D. Yang,et al.  Effect of ApoE Genotype on Response to Donepezil in Patients with Alzheimer’s Disease , 2008, Dementia and Geriatric Cognitive Disorders.

[3]  P. Raina,et al.  Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline , 2008, Annals of Internal Medicine.

[4]  M. Lai,et al.  How long can patients with mild or moderate Alzheimer’s dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population‐based study , 2008, European journal of neurology.

[5]  B. Winblad,et al.  A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementia , 2007, Expert review of neurotherapeutics.

[6]  A. Cedazo-Mínguez,et al.  Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities , 2007, Journal of cellular and molecular medicine.

[7]  Marek Bajda,et al.  Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. , 2007, Current medicinal chemistry.

[8]  J. Touchon,et al.  Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials? , 2007, The journal of nutrition, health & aging.

[9]  N. Relkin.  Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer’s disease , 2007, Expert review of neurotherapeutics.

[10]  B. Winblad,et al.  A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule , 2007, International journal of geriatric psychiatry.

[11]  H. Feldman,et al.  Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[12]  M. Boada,et al.  Relationship Between the Efficacy of Rivastigmine and Apolipoprotein E (ϵ4) in Patients With Mild to Moderately Severe Alzheimer Disease , 2006, Alzheimer disease and associated disorders.

[13]  Sture Eriksson,et al.  Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study , 2006, The Lancet.

[14]  B. Kee,et al.  Effect of the Apolipoprotein E ε4 Allele on the Efficacy and Tolerability of Galantamine in the Treatment of Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.

[15]  C. Marra,et al.  Apolipoprotein E ε4 Allele Differentiates the Clinical Response to Donepezil in Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.

[16]  Hendrik van den Bussche,et al.  Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.

[17]  M. Maggini,et al.  A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer’s disease , 2005, European Journal of Clinical Pharmacology.

[18]  David Ames,et al.  Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[19]  M. Petrovecki,et al.  ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study. , 2004, Collegium antropologicum.

[20]  K. Rockwood,et al.  Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  Roy W Jones,et al.  A multinational, randomised, 12‐week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease , 2004, International journal of geriatric psychiatry.

[22]  T. Einarson,et al.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[23]  R. Bullock,et al.  A MULTINATIONAL, RANDOMISED, 12‐WEEK, COMPARATIVE STUDY OF DONEPEZIL AND RIVASTIGMINE IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE , 2002, International journal of clinical practice.

[24]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[25]  G. Wilcock,et al.  Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial , 2000, BMJ : British Medical Journal.

[26]  E. Peskind,et al.  Galantamine in AD , 2000, Neurology.

[27]  G. Wilcock,et al.  Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease , 1998, International journal of geriatric psychiatry.

[28]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[29]  K. Davis,et al.  A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. , 1994, The American journal of psychiatry.

[30]  A. Heyman,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1993, Neurology.

[31]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[32]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[33]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[34]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[35]  M. Lawton,et al.  Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.

[36]  S. Katz,et al.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.

[37]  J. Birks.  Cholinesterase inhibitors for Alzheimer's disease. , 2006, The Cochrane database of systematic reviews.

[38]  G. Masotti,et al.  Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. , 2004, Archives of gerontology and geriatrics. Supplement.

[39]  S. Kudaravalli,et al.  Differential qualitative responses to rivastigmine in APOE ɛ4 carriers and noncarriers , 2004, The Pharmacogenomics Journal.

[40]  F. Campana,et al.  Alzheimer's disease and acetylcholinesterase inhibitor agents: a two-year longitudinal study. , 2004, Archives of gerontology and geriatrics. Supplement.

[41]  Luc Truyen,et al.  A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease , 2003, Drugs & aging.

[42]  Jeroen Aerssensa Peter Raeymaekersa Sean Lilienfeldb Hugo Geertsc,et al.  APOE Genotype : No Influence on Galantamine Treatment Efficacy Nor on Rate of Decline in Alzheimer ’ s Disease , 2001 .

[43]  S. Katz.  Studies of illness in the aged , 1963 .